240
Participants
Start Date
October 29, 2024
Primary Completion Date
January 31, 2026
Study Completion Date
February 28, 2026
HB-1
HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.
Telmisartan Only Product in Oral Dose Form
Telmisartan will be supplied as a single active pharmaceutical ingredient tablet.
Verapamil Only Product in Oral Dose Form
Verapamil will be supplied as a single active pharmaceutical ingredient tablet.
Placebo
Matched Placebo will be supplied as a tablet.
RECRUITING
East Sydney Doctors, Darlinghurst
RECRUITING
Momentum Clinical Research Darlinghurst, Darlinghurst
RECRUITING
Innovate Clinical Research, Waitara
RECRUITING
Westmead Hospital, Westmead
RECRUITING
Paratus Clinical Research Western Sydney, Blacktown
RECRUITING
Canopy Clinical Sutherland, Miranda
RECRUITING
Paratus Clinical Research Central Coast, Kanwal
RECRUITING
Novatrials, Kotara
RECRUITING
Canopy Clinical Wollongong, Wollongong
RECRUITING
Paratus Clinical Research Canberra, Canberra
RECRUITING
Multidisciplinary Alfred Psychiatry Research Clinic, Melbourne
RECRUITING
Ramsay Clinic Albert Road, Melbourne
RECRUITING
NeuroCentrix, Carlton
RECRUITING
Peninsula Therapeutic and Research Group, Frankston
RECRUITING
Grampians Health, Ballarat
RECRUITING
Paratus Clinical Research Brisbane, Herston
RECRUITING
Gold Coast University Hospital, Southport
RECRUITING
Mackay Hospital and Health Service, Mackay
RECRUITING
South Australian Health and Medical Research Institute, Adelaide
RECRUITING
Lyell McEwin Hospital, Elizabeth Vale
Honeybrains Biotech LLC
INDUSTRY